SONOMA BIOTHERAPEUTICS
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
SONOMA BIOTHERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2020-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.sonomabio.com
Total Employee:
101+
Status:
Active
Total Funding:
335 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Global Site Tag
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
ImmPACT Bio
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Kyverna Therapeutics
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
Opsin Biotherapeutics
Opsin Biotherapeutics develops a pipeline of opsin-based gene therapies for pain management
Pandion Therapeutics
Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
Simcha Therapeutics
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Piper Sandler
Piper Sandler investment in Series B - Sonoma BioTherapeutics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series B - Sonoma BioTherapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series B - Sonoma BioTherapeutics
Ally Bridge Group
Ally Bridge Group investment in Series B - Sonoma BioTherapeutics
Deep Track Capital
Deep Track Capital investment in Series B - Sonoma BioTherapeutics
Mirae Asset Global Investments
Mirae Asset Global Investments investment in Series B - Sonoma BioTherapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Sonoma BioTherapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Sonoma BioTherapeutics
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Sonoma BioTherapeutics
Lifeforce Capital
Lifeforce Capital investment in Series B - Sonoma BioTherapeutics
Key Employee Changes
Official Site Inspections
http://www.sonomabio.com Semrush global rank: 1.72 M Semrush visits lastest month: 13.85 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Sonoma BioTherapeutics"
About | Sonoma Biotherapeutics
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system.See details»
Sonoma BioTherapeutics - Crunchbase Company …
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on …See details»
Vision, Mission, and Values | Sonoma Biotherapeutics
We will build a professional organization that is creative, flexible, and adapts as the future unfolds. Focused on Cures We are driven by passion, boldness, accountability, and performance to fundamentally change people’s lives. We …See details»
Sonoma Biotherapeutics - LinkedIn
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system.See details»
Sonoma Biotherapeutics Company Profile 2024: …
Sonoma Biotherapeutics General Information Description. Developer of T-cell therapeutics designed to cure autoimmune and degenerative diseases. The company's therapeutics facilitate a state of self-tolerance by halting harmful …See details»
Sonoma BioTherapeutics - Craft
Sonoma BioTherapeutics has 5 employees across 2 locations and $70 m in total funding,. See insights on Sonoma BioTherapeutics including office locations, competitors, revenue, …See details»
News and Press - T1D Fund: A Breakthrough T1D Venture
Aug 4, 2021 More information at www.sonomabio.com. Read source version on Business Wire. Contacts. Sarah Spencer [email protected] 215-733-9375. Danielle Cantey ...See details»
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone …See details»
Careers | Sonoma Biotherapeutics
To external Recruiters or Talent Acquisition Agencies: If you would like to supply candidate resumes to Sonoma Biotherapeutics, please work directly through Sonoma’s Talent …See details»
Sonoma Bio Co-Founder and Chief Executive Officer ... - Business …
May 4, 2023 Brian Crawford Sonoma Biotherapeutics [email protected] 650-238-7876 Danielle Cantey Evoke Canale [email protected] 619-826-4657 Site …See details»
Sonoma Biotherapeutics launches with $40 million in Series A …
Feb 6, 2020 SOUTH SAN FRANCISCO, Calif. and SEATTLE, Feb. 6, 2020 /PRNewswire/ -- Sonoma Biotherapeutics, a privately held company developing regulatory T cell (Treg) …See details»
Sonoma Biotherapeutics Announces FDA Clearance of …
Jun 8, 2022 Brian Crawford Sonoma Biotherapeutics [email protected] 650-238-7876 Danielle Cantey Evoke Canale [email protected] 619-826-4657 Site NavigationSee details»
Sonoma Biotherapeutics Enters Long-Term Lease Agreement to …
Aug 24, 2022 Brian Crawford Sonoma Biotherapeutics [email protected] 650-238-7876 Danielle Cantey Evoke Canale [email protected] 619-826-4657 Site …See details»
Sonoma BioTherapeutics CEO and Key Executive Team - Craft
Sonoma BioTherapeutics's Chief Executive Officer and President is Jeff Bluestone. Other executives include Douglas Sheehy, Chief Legal Officer and Secretary; Mark Eisner, Chief …See details»
Leadership - Sonoma Biotherapeutics
Jeffrey Bluestone, Ph.D. is one of the leading immunologists in the field of T-cell activation and immune tolerance research that has led to the development of multiple immunotherapies, …See details»
Sonoma Biotherapeutics: rallying the regulators - Nature
Jun 16, 2021 Therapeutic applications of T cells have been focused up until now on their role as immunological ‘attack dogs’ that can be trained to seek and destroy foreign invaders or …See details»
People & Culture | Sonoma Biotherapeutics
Sonoma Bio is founded and led by pioneers in T reg biology and cell therapy. This is their life’s work and they’re building an equally passionate and collaborative team to execute on …See details»
Sonoma Bio bags $265M to rev up cell therapies for arthritis, …
Aug 4, 2021 After a modest $40 million debut in early 2020, Sonoma Biotherapeutics is grabbing a whopping $265 million to bankroll a pipeline of cell therapies for autoimmune diseases, …See details»
Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed …
Aug 4, 2021 Sarah Spencer [email protected] 215-733-9375 Danielle Cantey Canale Communications [email protected] 619-826-4657 Social Media …See details»